Lebrikizumab Demonstrates Consistent Efficacy at 16 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis Regardless of Baseline Disease Severity

Linda Stein Gold; Kilian Eyerich; Howard Sofen; Pedro Herranz; Leon Kircik; Tony Bewley; Eric Wolf; Gaia Gallo; Yuxin Ding; Fan Emily Yang; Ignasi Pau-Charles; Melinda Gooderham

doi:10.25251/skin.7.supp.274

Lebrikizumab Demonstrates Consistent Efficacy at 16 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis Regardless of Baseline Disease Severity

Linda Stein Gold, Kilian Eyerich, Howard Sofen, Pedro Herranz, Leon Kircik, Tony Bewley, Eric Wolf, Gaia Gallo, Yuxin Ding, Fan Emily Yang, Ignasi Pau-Charles, Melinda Gooderham

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND Lebrikizumab is a monoclonal antibody that binds with high affinity and slow dissociation rate to IL-13,thereby blocking the downstream effects ofIL-13 with high potency1 Lebrikizumab has demonstrated clinical benefit in patients with moderate-to-severe AD in the randomized, placebo-controlled, Phase 3 ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967) trials2,3OBJECTIVE To assess efficacy of lebrikizumab in the ADvocate1 and ADvocate2 trials within subgroups of patients with moderate (IGA=3) vs.

Original language	English
Pages (from-to)	s274-s274
Journal	SKIN: Journal of Cutaneous Medicine
Volume	7
Issue number	6
DOIs	https://doi.org/10.25251/skin.7.supp.274
State	Published - Nov 2023
Externally published	Yes

Access to Document

10.25251/skin.7.supp.274

Cite this

Gold, L. S., Eyerich, K., Sofen, H., Herranz, P., Kircik, L., Bewley, T., Wolf, E., Gallo, G., Ding, Y., Yang, F. E., Pau-Charles, I., & Gooderham, M. (2023). Lebrikizumab Demonstrates Consistent Efficacy at 16 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis Regardless of Baseline Disease Severity. SKIN: Journal of Cutaneous Medicine, 7(6), s274-s274. https://doi.org/10.25251/skin.7.supp.274

@article{1e73a224cab547958f295f53db941a95,

title = "Lebrikizumab Demonstrates Consistent Efficacy at 16 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis Regardless of Baseline Disease Severity",

abstract = "BACKGROUND Lebrikizumab is a monoclonal antibody that binds with high affinity and slow dissociation rate to IL-13,thereby blocking the downstream effects ofIL-13 with high potency1 Lebrikizumab has demonstrated clinical benefit in patients with moderate-to-severe AD in the randomized, placebo-controlled, Phase 3 ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967) trials2,3OBJECTIVE To assess efficacy of lebrikizumab in the ADvocate1 and ADvocate2 trials within subgroups of patients with moderate (IGA=3) vs.",

author = "Gold, {Linda Stein} and Kilian Eyerich and Howard Sofen and Pedro Herranz and Leon Kircik and Tony Bewley and Eric Wolf and Gaia Gallo and Yuxin Ding and Yang, {Fan Emily} and Ignasi Pau-Charles and Melinda Gooderham",

year = "2023",

month = nov,

doi = "10.25251/skin.7.supp.274",

language = "English",

volume = "7",

pages = "s274--s274",

journal = "SKIN: Journal of Cutaneous Medicine",

issn = "2574-1624",

publisher = "National Society for Cutaneous Medicine",

number = "6",

}

Gold, LS, Eyerich, K, Sofen, H, Herranz, P, Kircik, L, Bewley, T, Wolf, E, Gallo, G, Ding, Y, Yang, FE, Pau-Charles, I & Gooderham, M 2023, 'Lebrikizumab Demonstrates Consistent Efficacy at 16 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis Regardless of Baseline Disease Severity', SKIN: Journal of Cutaneous Medicine, vol. 7, no. 6, pp. s274-s274. https://doi.org/10.25251/skin.7.supp.274

TY - JOUR

T1 - Lebrikizumab Demonstrates Consistent Efficacy at 16 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis Regardless of Baseline Disease Severity

AU - Gold, Linda Stein

AU - Eyerich, Kilian

AU - Sofen, Howard

AU - Herranz, Pedro

AU - Kircik, Leon

AU - Bewley, Tony

AU - Wolf, Eric

AU - Gallo, Gaia

AU - Ding, Yuxin

AU - Yang, Fan Emily

AU - Pau-Charles, Ignasi

AU - Gooderham, Melinda

PY - 2023/11

Y1 - 2023/11

N2 - BACKGROUND Lebrikizumab is a monoclonal antibody that binds with high affinity and slow dissociation rate to IL-13,thereby blocking the downstream effects ofIL-13 with high potency1 Lebrikizumab has demonstrated clinical benefit in patients with moderate-to-severe AD in the randomized, placebo-controlled, Phase 3 ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967) trials2,3OBJECTIVE To assess efficacy of lebrikizumab in the ADvocate1 and ADvocate2 trials within subgroups of patients with moderate (IGA=3) vs.

AB - BACKGROUND Lebrikizumab is a monoclonal antibody that binds with high affinity and slow dissociation rate to IL-13,thereby blocking the downstream effects ofIL-13 with high potency1 Lebrikizumab has demonstrated clinical benefit in patients with moderate-to-severe AD in the randomized, placebo-controlled, Phase 3 ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967) trials2,3OBJECTIVE To assess efficacy of lebrikizumab in the ADvocate1 and ADvocate2 trials within subgroups of patients with moderate (IGA=3) vs.

UR - http://www.scopus.com/inward/record.url?scp=85177818553&partnerID=8YFLogxK

U2 - 10.25251/skin.7.supp.274

DO - 10.25251/skin.7.supp.274

M3 - Article

AN - SCOPUS:85177818553

SN - 2574-1624

VL - 7

SP - s274-s274

JO - SKIN: Journal of Cutaneous Medicine

JF - SKIN: Journal of Cutaneous Medicine

IS - 6

ER -

Lebrikizumab Demonstrates Consistent Efficacy at 16 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis Regardless of Baseline Disease Severity

Abstract

Access to Document

Other files and links

Fingerprint

Cite this